P/E ratio for Cocrystal Pharma (COCP)
P/E ratio as of July 2025 (TTM): -1.06
According to Cocrystal Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.06049. At the end of 2024 the company had a P/E ratio of -1.89.
P/E ratio history for Cocrystal Pharma from 2012 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -1.89 | 105.43% |
| 2023 | -0.9198 | 124.99% |
| 2022 | -0.4088 | -99.16% |
| 2021 | -48.8 | 483.63% |
| 2020 | -8.35 | 2583.6% |
| 2019 | -0.3113 | -85.59% |
| 2018 | -2.16 | -98.92% |
| 2017 | -200 | 5330.52% |
| 2016 | -3.68 | -62.26% |
| 2015 | -9.76 | -55.86% |
| 2014 | -22.1 | 21.65% |
| 2013 | -18.2 | -38.87% |
| 2012 | -29.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Merck MRK | 12.0 | -1,229.67% | 🇺🇸 USA |
 USANA USNA | 16.5 | -1,654.81% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 18.5 | -1,848.20% | 🇺🇸 USA |
 Nature's Sunshine Products NATR | 21.5 | -2,131.52% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.